The FGFR-inhibitor derazantinib (DZB) is active in PDX-models of GI-cancer with specific aberrations in FGFR

McSheehy, P; Bachmann, F; Forster-Gross, N; El Shemerly, M; Roceri, M; Kellenberger, L; Lane, HA

JOURNAL OF CLINICAL ONCOLOGY, 2020; 38 (4):

Abstract

Full Text Link


Links

期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索